21 – 40 of 42
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 1996
-
Mark
Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group
(
- Contribution to journal › Article
- 1995
-
Mark
Primary surgery in ovarian cancer : current opinions
(
- Contribution to journal › Scientific review
-
Mark
Identification of small areas of solid growth has a strong prognostic impact in differentiated endometrial carcinomas. A histopathologic and morphometric study
(
- Contribution to journal › Article
-
Mark
Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting : the Nordic experience. The Nordic Antiemetic Trial Group
(
- Contribution to journal › Article
- 1994
-
Mark
A population-based survey of ovarian malignancies in the southeast health care region of Sweden 1984-1987
(
- Contribution to journal › Article
-
Mark
Granulosa cell tumors of the ovary : prognostic factors and outcome
(
- Contribution to journal › Article
-
Mark
Mucinous borderline and malignant tumors of the ovary. A clinicopathologic and DNA ploidy study of 92 cases
(
- Contribution to journal › Article
-
Mark
Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy
(
- Contribution to journal › Article
-
Mark
A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis
(
- Contribution to journal › Article
-
Mark
Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting--the Nordic experience
(
- Contribution to journal › Article
- 1993
-
Mark
Monitoring CA 125 serum levels during early chemotherapy is an excellent prognostic method in advanced ovarian cancer
(
- Contribution to journal › Article
-
Mark
Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer
(
- Contribution to journal › Article
-
Mark
Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma
(
- Contribution to journal › Article
-
Mark
Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin
1993) In Annals of oncology : official journal of the European Society for Medical Oncology 4(Suppl 3). p.31-34(
- Contribution to journal › Article
- 1992
-
Mark
Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125
(
- Contribution to journal › Article
-
Mark
Nuclear morphometry : a strong prognostic factor for survival after secondary surgery in advanced ovarian cancer
(
- Contribution to journal › Article
- 1991
-
Mark
Postmenopausal extragenital choriocarcinoma. A case report and review of the literature
(
- Contribution to journal › Scientific review
- 1990
-
Mark
Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma
(
- Contribution to journal › Article
- 1989
-
Mark
The use of chordotomy to treat pain from gynecologic cancer
(
- Contribution to journal › Article
- 1983
-
Mark
Applications of Laser Techniques To Combustion Diagnosis
(
- Contribution to journal › Article